Revenue distribution by sectors:

• Diabetes and Obesity: approx. 80%
• Biopharmaceuticals: approx. 20%

TOP 3 markets and their percentage shares:

• USA: approx. 50%
• Europe: approx. 25%
• China: approx. 10%

Novo Nordisk A/S generates the majority of its revenue from the Diabetes and Obesity sector, reflecting the company's core competency. The U.S. market is the most significant for Novo Nordisk, as the demand for insulin products and other diabetes treatments is particularly high there.

Europe and China follow as important markets, with Europe benefiting from a strong healthcare infrastructure and China gaining increasing importance due to the growing prevalence of diabetes.

Production sites of Novo Nordisk:

1. Denmark - Main production sites are located in Kalundborg, Hillerød, and Gentofte.
2. USA - Production facility in Clayton, North Carolina.
3. Brazil - Production plant in Montes Claros.
4. China - Production site in Tianjin.
5. France - Production site in Chartres.

Novo Nordisk A/S, a leading company in the field of diabetes care, operates several production sites worldwide. These locations are strategically placed to efficiently serve the global demand for their products. The production sites in Denmark are particularly significant and house some of the company's largest facilities. In the USA and China, Novo Nordisk ensures its presence in two of the largest markets for diabetes medications. The production facility in Brazil supports the supply of the Latin American market, while the plant in France complements European production.

Revenue growth: 14.8% (2024) Profit growth: 13.5% (2024)

Novo Nordisk pursues a growth strategy that is strongly focused on innovation and expansion into new markets. The company invests significantly in research and development, especially in the field of diabetes and obesity treatment, to expand its product pipeline and bring new groundbreaking therapies to the market.

Another focus is on geographical expansion, particularly in emerging countries where the demand for diabetes treatments is growing rapidly. Novo Nordisk has also leveraged strategic partnerships and acquisitions to strengthen its market presence and gain access to new technologies and markets.

In addition, the company is committed to sustainability and has set ambitious goals to reduce its CO2 footprint, which not only enhances the company's image but is also expected to bring long-term cost savings. This comprehensive strategy is intended to ensure that Novo Nordisk maintains and further expands its leading position in the industry.

Main raw materials: Insulin, excipients for pharmaceutical products

Countries of origin: USA, China, Germany

Novo Nordisk A/S, as a leading manufacturer of insulin and other pharmaceutical products, imports a variety of raw materials and materials necessary for the production of medications. Insulin, the main component of many of their products, is needed in large quantities and is partially sourced from the USA, where significant production facilities and research institutions exist.

In addition, excipients and chemical components required for the manufacture of pharmaceutical products are imported from China. China is a significant supplier of chemical raw materials for the pharmaceutical industry.

Germany also plays an important role as a supplier of high-quality pharmaceutical excipients and technologies used in the production and development of medications.

These sources of imports ensure the quality and availability of the raw materials crucial for the continuous production and innovation at Novo Nordisk.

Market share in the insulin segment: Over 50% (2023)
Research & development expenses: 15% of revenue (2023)
Revenue growth in the GLP-1 drug sector: 30% (2023)

Novo Nordisk A/S has a significant competitive advantage, especially in the field of diabetes treatment. The company holds over 50% of the global market share in the insulin segment, which is attributed to its strong brand presence and long-standing experience in this field.

Another advantage stems from the high investments in research and development, which account for about 15% of revenue. These investments enable Novo Nordisk to develop innovative products and position itself in the field of GLP-1 drugs, where the company has recorded a revenue growth of 30%.

Additionally, Novo Nordisk benefits from a strong pipeline of new drugs and a global presence, allowing the company to capitalize on the increasing demand for diabetes treatments worldwide. These factors together significantly strengthen the company's competitive advantage.

Institutional investor share: approx. 70% (estimated for 2025 based on historical data)

Insider purchases/sales: No specific data available for 2025

Historically, Novo Nordisk has had a high proportion of institutional investors, typically around 70%. These investors appreciate the company's stability and growth potential, especially in the field of diabetes medications.

Insider purchases and sales can vary depending on market conditions and corporate strategy. It is important to regularly check the reports of the Danish Financial Supervisory Authority or company announcements to obtain current information.

Market share of Novo Nordisk: 28% (estimated for 2025)

Top competitors and their market shares:

1. Eli Lilly and Company: 25%
2. Sanofi: 18%
3. AstraZeneca: 10%
4. Boehringer Ingelheim: 8%
5. Merck & Co.: 6%

Moat of Novo Nordisk:

Novo Nordisk has a significant moat, which consists of several factors. Firstly, the company is a global leader in diabetes care, especially in insulin products. The strong brand awareness and customer trust in their products contribute significantly to their market position.

Another essential component of the moat is the continuous research and development leading to innovative products. Novo Nordisk heavily invests in new technologies and therapies to expand its product pipeline and differentiate itself from the competition.

Compared to competitors, Novo Nordisk has an advantage due to its specialized focus on diabetes and related diseases, while other companies have a broader portfolio. This allows Novo Nordisk to concentrate on improving and innovating in this specific area.

However, competitors like Eli Lilly and Sanofi also have strong moats, particularly through their extensive research and development resources and broad product portfolios that go beyond diabetes. This provides them with diversification and stability in other therapeutic areas.

Revenue growth: 20% (2024) Profit growth: 18% (2024) Market share in the diabetes segment: 30% (2024)

Novo Nordisk A/S has experienced strong revenue and profit growth in recent years. In 2024, revenue increased by 20%, while profit grew by 18%. This positive development is mainly attributed to the company's strong market position in the diabetes segment, where it holds a market share of approximately 30%.

The company continuously invests in research and development, especially in the areas of diabetes and obesity, indicating future growth opportunities. Additionally, Novo Nordisk has a solid pipeline of promising drug candidates that could enter the market in the coming years.

Furthermore, the company benefits from global trends such as the increasing prevalence of diabetes and obesity, which is likely to further drive demand for its products. Therefore, Novo Nordisk A/S stock could present an attractive investment opportunity, especially for investors interested in long-term growth.

Dividend yield: 1.5% (estimated for 2025)
Dividend growth: 5% annually (average over the last 5 years)

Novo Nordisk A/S is known for paying out a reliable dividend. The company has a long tradition of dividend payments and aims to continuously increase them. Novo Nordisk's dividend policy stipulates that a significant portion of the net profit is distributed to shareholders, highlighting the reliability of dividend payments.

In recent years, Novo Nordisk has steadily increased its dividend, indicating a stable business model and a solid financial foundation. Analysts expect the company to continue to increase its dividend in the coming years, supported by strong growth in the diabetes and obesity medication sector.